India markets close in 1 hour 58 minutes

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
115.83+0.43 (+0.37%)
At close: 4:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close115.40
Open115.36
Bid0.00 x 900
Ask0.00 x 1300
Day's range114.52 - 115.94
52-week range79.11 - 118.28
Volume3,472,642
Avg. volume6,985,917
Market cap204.581B
Beta (5Y monthly)0.80
PE ratio (TTM)39.76
EPS (TTM)2.91
Earnings date29-Jul-2021 - 02-Aug-2021
Forward dividend & yield5.20 (4.51%)
Ex-dividend date14-Apr-2021
1y target est124.08
  • SOLITON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SOLY and Encourages Investors to Contact the Firm
    GlobeNewswire

    SOLITON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SOLY and Encourages Investors to Contact the Firm

    NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Soliton, Inc. (NASDAQ: SOLY) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by AbbVie, Inc. (NYSE: ABBV). Click here to learn more and participate in the action. On May 10, 2021, Soliton announced that it had signed an agreement to be acquired by AbbVie for approximately $550 million. Pursuant to the merger agreement, Soliton stockholders will receive $22.60 in cash for each share of Soliton common stock owned. Bragar Eagel & Squire is concerned that Soliton’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Soliton’s stockholders. If you own shares of Soliton and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information:Bragar Eagel & Squire, P.C.Melissa Fortunato, Esq.Alexandra Raymond, Esq.investigations@bespc.comwww.bespc.com

  • SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Soliton, Inc. Buyout
    GlobeNewswire

    SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Soliton, Inc. Buyout

    WILMINGTON, Del., May 10, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Soliton, Inc. (“Soliton”) (NASDAQ GS: SOLY) regarding possible breaches of fiduciary duties and other violations of law related to Soliton’s agreement to be acquired by AbbVie Inc. (“AbbVie”) (NYSE: ABBV). Under the terms of the agreement, Soliton’s shareholders will receive $22.60 in cash per share. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-soliton-inc. You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com. Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide. Attorney advertising. Prior results do not guarantee a similar outcome. CONTACT: Rigrodsky Law, P.A.Seth D. RigrodskyGina M. Serra(888) 969-4242 (Toll Free)(302) 295-5310Fax: (302) 654-7530info@rl-legal.com https://rl-legal.com

  • Healthcare ETFs on Radar As Q1 Earnings Unfold
    Zacks

    Healthcare ETFs on Radar As Q1 Earnings Unfold

    Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.